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Acute Affective and Physiological Response to Different Exercise-Training
Protocols in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Amanda Katy Rizk
Current pulmonary rehabilitation (PR) guidelines advocate high-intensity exercise
training for individuals with chronic obstructive pulmonary disease (COPD), yet this
approach has been shown to be unachievable in a large proportion of patients.
Alternative approaches, such as training at the ventilatory threshold, have been
proposed as more tolerable, less unpleasant, and thus possibly easier to comply with for
this clientele. This assumption needs to be verified. The purpose of the present study
was to compare, in COPD patients, the acute affective and physiological response to
high-intensity training (CT80) versus training at the ventilatory threshold (CTVT).
Thirteen subjects were randomly assigned to perform 40 minutes (including warm-up
and cool-down) of either high-intensity exercise training at 80% of peak work rate (CT80)
or training at the ventilatory threshold (CTVT) on a cycle ergometer. Affective response
to the exercise bout was measured using the Positive and Negative Affect Schedule
(PANAS) and the Global Vigor and Affect Instrument (GVA). Physiological response to
the same bout was measured breath by breath with a portable metabolic system.
Repeated-measures general linear models and mixed models were conducted using
SAS. Positive affect scores from the PANAS increased from pre-, to end-, to post-
exercise (time effect) (F=17.56, p=0.0005), but this increase was significant for the
CTVT group only (time by intervention interaction) (F=5.85, p=0.02). No significant time
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or interaction effect was observed for global affect or global vigor from the GVA. In
addition, no significant difference in physiological response was observed between CT80
and CTVT. Results from this pilot study suggest that affect improves after an exercise-
training bout in COPD patients, especially when the protocol used is CTVT. The acute
physiological and symptomatic response to CT80 and CTVT appears to be similar.
Keywords: COPD, affective response, physiological response, exercise training.
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1.1 What is Chronic Obstructive Pulmonary Disease?
The term "chronic obstructive pulmonary disease" (COPD) represents a cluster of
respiratory disorders which are preventable and manageable, associated with
progressive and partially irreversible chronic airflow limitation [1-4]. The main symptoms
of COPD, which typically appear in middle adulthood (> 55 years), are shortness of
breath, cough, and sputum production [5-9]. The two most common underlying disorders
that lead to COPD are chronic bronchitis and emphysema [4]. Chronic bronchitis is
clinically defined as the presence of cough and sputum production for at least 3 months
in each of 2 consecutive years [1, 4]. Although chronic bronchitis is a main cause of
COPD, it does not necessarily lead to chronic airflow limitation [1, 4]. Emphysema is
characterized by the destruction of the gas exchanging surfaces of the lungs (alveoli) [1 ,
4]. Emphysema is a pathological term that is often used clinically to designate COPD;
however, emphysema refers specifically to the destruction of the alveoli, which
represents only one of many abnormalities associated with COPD [1]. In actuality,
COPD is a combination of airway disease (bronchitis) and parenchymal destruction
(emphysema) with the contributions of each varying from one patient to another [1].
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1.2 Epidemiology:
1.2.1 Prevalence, Incidence and Economic Burden
COPD is currently the fourth leading cause of death in the world [5, 9]. Latest
national estimates suggest that it is the fourth and fifth leading cause of death in
Canadian men and women, respectively [1O]. The province of Quebec has the second
highest COPD-related mortality rate in the country after the Northwest Territories [6].
Close to 750,000 Canadians state that they have received a diagnosis of COPD from
their physician, which accounts for approximately 4.4% of the population [3, 10]. The
actual incidence and prevalence is probably higher since COPD is not diagnosed until
clinically apparent and thus fairly advanced [6, 10]. The proportion of individuals affected
by COPD increases steadily with age in men and women [6]. Hence, the total morbidity
and mortality associated with this disease is expected to rise over the next two decades
as the population ages [6, 8].
COPD imposes a heavy economic burden on the Canadian healthcare system.
In 2004-05, respiratory diseases ranked third as a major cause of hospitalization in men
and women, behind circulatory diseases and digestive disorders; among respiratory
diseases, COPD ranked first in that category along with influenza/pneumonia [10]. ¡n
2004-05, the average length of hospital stay for COPD was 9.6 days for individuals aged
55 and over [10]. Overall, respiratory diseases account for close to 7% ($8.63 billion) of




The identification and understanding of the many risk factors of COPD is a
crucial step towards developing treatment and preventative care aimed at this patient
population. Cigarette smoking, through the inhalation of noxious particles or gases, is by
far the strongest risk factor for this disease [5, 6, 9]; it is believed to be responsible for
80-90% of COPD cases [6]. In fact, in the Obstructive Lung Disease in North Sweden
(OLIN) study, it was reported that approximately 50% of smokers eventually develop
COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [11]. The risk of cigarette smoking is dose-dependent and is often
represented as total pack-years smoked (calculated by multiplying the number of packs
smoked per day by the number of years smoked) [1]. The discovery of smoking as a key
risk factor has led to the incorporation of smoking cessation programs as a preventative
treatment as well as an essential intervention for COPD patients [1]. Although smoking is
the strongest and most-studied risk factor, it is possible for non-smokers to acquire this
disease [1].
1.3.2 Genetic
The best documented genetic risk factor for COPD is a genetic deficiency of
alpha- 1 -antitrypsin which predisposes individuals to emphysema [1]. This genetic
deficiency affects approximately one in 2000-5000 individuals and is most commonly
seen in individuals of Northern European decent [1, 12]. The main function of alpha-1-
antitrypsin is to protect the lung from proteolytic damage from neutrophil elastase [12].
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With a deficiency of alpha-1 -antitrypsin, a greater secretion of neutrophil elastase occurs
during inflammation [13]. Neutrophil elastase is an enzyme that promotes or leads to
proteolysis (a breakdown of protein) thereby destroying bacteria and host tissue [13].
Individuals with this genetic component have a risk of developing emphysema and a
decline in lung function [1]. This risk is amplified if individuals with this rare deficiency
smoke, which clearly reveals the importance of the interaction between the genetic and
environmental risk factors.
Other genes, which regulate the production of transforming growth factor beta 1
(TGF-ß1) [14], microsomal epoxide hydrolase 1 (mEPHXI) [15], and tumor necrosis
factor alpha (TNFa) [16], have also been associated with the pathogenesis of COPD.
However, these findings have been largely inconsistent and further studies are needed
to clarify the association of these genetic factors with the disease [1].
1.3.3 Occupational exposure to dusts and fumes
Occupational exposure to organic and inorganic dusts and chemicals (vapors,
irritants, and fumes) are known to cause COPD, independent of smoking history [1] In
addition, they appear to act additively to smoking to increase the possibility of acquiring
this disease [1]. According to the American Thoracic Society [17], occupational exposure
accounts for up to 20% of all COPD cases. This risk varies depending on particle type,
size, composition, and exposure time to these irritants [1].
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1.3.4 Air pollution
Indoor and outdoor air pollution also contributes to the risk of developing COPD
[1]. Although the risk of COPD due to air pollution is lesser than the risk due to cigarette
smoking, it continues to remain an underestimated risk factor [1]. Indoor air pollution can
be caused by the burning of wood, animal dung, crop residues, and coal in open fires
and poorly operating stoves [1]. The risk of indoor air pollution caused by biomass
cooking and heating continues to grow especially among women in developing countries
who continue to use biomass and coal as their main source of energy for cooking and
heating, among other household needs [1]. In addition, high levels of urban air pollution
caused by fossil fuel combustion mainly from vehicle emissions is considered as a risk
factor for COPD; however its role in causing this disease remains unclear [1]. Among the
many questions needed to be answered includes the effect of short duration, high-peak
exposures compared with long duration, low-level exposures [1].
1.3.5 Infection
Viral and bacterial infections may also contribute as a risk factor for COPD as
well as play a major role in exacerbations [1]. A history of childhood respiratory tract
infections is associated with increased respiratory symptoms and decreased lung
function [1]. Childhood infections are also related to having a low birth weight, which is
also associated with COPD [1]. Furthermore, HIV infection and a history of tuberculosis
have also been associated with airflow obstruction in COPD patients [18, 19].
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1.4 Pathology, Pathogenesis and Pathophysiology of COPD
1.4.1 Pathology and Pathogenesis
The chain of events leading to COPD begins with specific risk factors linked to
this disease which trigger inflammatory cells such as lymphocytes (T CD4+, T CD8+),
macrophages, and neutrophils. These cells can then potentially release certain
inflammatory mediators such as lipid mediators (leukotriene B4), chemokines
(interleukin-8), cytokines (interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha),
and growth factors (transforming growth factor-beta) interacting with structural cells in
the airways and lung parenchyma [1]. This interaction induces chronic inflammation in
various regions of the lung and structural changes resulting from recurring tissue
damage and repair [1]. In addition, chronic inflammation can be brought on by oxidative
stress and an imbalance between proteases (which break down connective tissue) and
antiproteases (which protect against this breakdown), at the favour of the former [1 , 2].
For example, this imbalance may cause the breakdown of elastin to occur [2]. A
breakdown of elastin diminishes the elastic ability of the lungs, which is a classic sign of
emphysema [1, 2]
In general, pathological structural changes occur in four distinct regions of the
lung: the proximal (central) airways, the peripheral airways, the lung parenchyma, and
the pulmonary vasculature [1, 2]. The proximal airways refer to the trachea and bronchi
with an internal diameter greater than 2 mm [1]. Structural changes occurring in this
region include an increase in goblet cells, hypersecretion of mucus caused by enlarged
submucosal glands, and squamous metaplasia of the epithelium (the reversible
replacement of columnar epithelium with squamous epithelium thereby altering the
normal homeostatic state) [1]. The peripheral airways include the bronchioles with an
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internal diameter less than 2 mm [1]. Potential structural changes which may occur in
this region include inflammation, thickening of the airway wall, narrowing of the airway,
peribronchial fibrosis, and exudate, which is fluid accumulation in areas of inflammation
[1]. Lung parenchyma consists of the respiratory bronchioles and alveoli [1]. Structural
changes in this region caused by COPD include destruction of the alveolar wall and
apoptosis (programmed death) of epithelial and endothelial cells [1]. The pulmonary
vasculature refers to all the vessels (arteries, veins, and capillaries) found in the lungs,
and possible structural changes in this region include an increase in smooth muscle
mass, endothelial cell dysfunction accompanied with thickening of the intima, which can
all lead to pulmonary hypertension [1]. It is important to note that the extent to which
each region is affected varies from one COPD patient to another [2].
1.4.2 Pathophysiology
1.4.2.1 Expiratory flow limitation and Lung Hyperinflation
In order to comprehend the complexity of expiratory flow limitation and lung
hyperinflation, which are classic features of COPD, it is important to first gain
background knowledge of basic lung volumes, capacities, and flow rates. Figure 1
illustrates the basic lung volumes and capacities. There are four basic lung volumes as
well as four basic lung capacities. When one is breathing normally, at rest, the regular
inspiratory/expiratory cycle of breathing is termed tidal breathing [20]. The volume of air
breathed in and out through each breath during tidal breathing is called tidal volume (VT).
Inspiratory reserve volume (IRV) is the maximum amount of additional air that can be
inspired from the end of a normal inspiration, while expiratory reserve volume (ERV) is
the maximum amount of additional air that can be expired from the end of a normal
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expiration. Finally, residual volume (RV) is the amount of air remaining in the lungs after
a maximal expiration [20]. In normal lungs, this point represents the relaxation of all
respiratory muscles in addition to the balance of recoil pressures between the lungs and
chest wall [20].
Lung capacities are composed of two or more lung volumes. Inspiratory capacity
(IC) is the amount of air that can be inhaled forcefully subsequent to a normal expiration
and corresponds to the sum of VT and IRV [20]. At the end of a normal expiration, the
volume of air contained in the lungs is termed the functional residual capacity (FRC) and
corresponds to the sum of RV and ERV [20]. Vital capacity (FVC) is the amount of air
that can be forcefully exhaled following a maximal inspiration and corresponds to the
sum of ERV, VT, and IRV [21]. Finally, total lung capacity (TLC) is the total volume of air
that can be contained in the lungs at the end of a maximal inspiration and corresponds










Figure 1.1 Basic lung volumes and capacities. TLC: total lung capacity; IC: inspiratory
capacity; FRC: functional residual capacity; RV: residual volume; IRV: inspiratory
reserve volume; VT: tidal volume; ERV: expiratory reserve volume; RV: residual volume;
VC: vital capacity.
Taken from Ferguson et al. [20]
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Several flow rates can be measured, yet the two of greatest interest and clinical
usefulness in COPD are forced expiratory volume in one second (FEV1) and forced vital
capacity (FVC). Both of these measurements can be obtained through spirometry with a
FVC manoeuvre, which requires patients to forcefully inspire and expire as much air as
possible following certain standards [22]. FEV1 represents the amount of air that is
exhaled in the first second of the FVC manoeuvre [21]. Its value in litres and in
percentage of the normal predicted value is pivotal in the classification of COPD disease
severity. Likewise, the ratio of FEV1 to FVC, which provides an indication of the
proportion of FVC exhaled in the first second of expiration, is critical in the diagnosis of
COPD [20].
The pathophysiology of COPD is not completely understood. However, the
hallmark feature of this disease is expiratory flow limitation as shown by a reduction in
the FEV1 / FVC ratio often accompanied by a reduction in FEV1 [23]. This outcome
arises due to intrinsic and extrinsic factors that increase airway resistance [23]. Such
factors include mucosal inflammation and oedema, secretions, extraluminal compression
by adjacent overinflated alveoli, etc [23]. Emphysema further limits respiration by
reducing the elastic recoil in the lungs thereby increasing the expiratory pressure making
it progressively more difficult to expire [23]. Patients with COPD also often have an
increased physiological dead space because of the destruction of alveolar wall integrity
and concurrent loss of gas exchange surfaces [24]. Due to this physiological limitation,
patients with COPD have an increased ventilatory requirement (VE) for any given task
[25]. In contrast to their healthy counter-parts, COPD patients often achieve levels of VE
that reach their predicted maximum voluntary ventilation (MVV) on exertion due to flow
obstruction [26-28]. The ratio of VE/MVV can therefore reach 100% in this patient
population during exercise, whereas it rarely exceeds 80% in healthy individuals [27].
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This also means that VE can be a limiting factor to exercise in COPD patients, which is
not the case in healthy individuals.
Patients with COPD also often experience some degree of lung hyperinflation,
also commonly known as air trapping, which is intimately linked to the sensation of
dyspnoea [20]. Hyperinflation can be thought of as having two main components; static
hyperinflation and dynamic hyperinflation. Static hyperinflation is caused by a loss of
elasticity in the lung parenchyma (alveoli, alveolar duct, and bronchioles), thereby
causing a reduced amount of recoil pressure from the lungs to counter the pressure
exerted by the chest wall [20]. Static hyperinflation can be considered if values of resting
functional residual capacity (FRC) or end-expiratory lung volume (EELV) are elevated
above normal values (Figure 2) [20]. Dynamic hyperinflation refers to an elevation of
EELV, which could be brought on by exercise or anything that would increase VE (e.g.,
emotional stress) [29]. It is caused by additional air trapping within the lungs following
each breath due to the patient being unable to completely empty their lungs upon
exhalation, therefore causing disequilibrium between inspired and expired volumes [20].
Several factors could be associated with the degree of hyperinflation in COPD patients
such as inflammation, increased mucus production, narrowed airways, and possible
collapsing of the airways [20, 30]. Both the static and dynamic effects contribute to lung
hyperinflation in this disease, yet dynamic hyperinflation typically occurs more frequently.
Additionally, dynamic hyperinflation can occur independent of static hyperinflation [20].
Hyperinflation can cause several unfavourable effects, including an increase in the
amount of work needed to breathe, an impairment in gas exchange between alveoli and
blood vessels, and possible respiratory muscle dysfunction [20].
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1.4.2.2 Gas Exchange Limitations
Several limitations exist concerning gas exchange in COPD patients. In an
emphysematous lung, the destruction of alveoli inhibits oxygen (O2) from entering the
capillaries in order to reach the systemic circulation, and carbon dioxide (CO2) from
entering the alveoli so as to be expired upon exhalation. This leads to a lack of available
O2 in the systemic circulation as well as an abundance of trapped CO2 in the lungs and
circulation. This faulty mechanism thereby results in hypoxemia (a decreased partial
pressure of O2 in the blood) and hypercapnia (increased levels of CO2 in the blood) [1]. In
most cases, the transfer of gases worsens as disease severity progresses [1]. The
arterial perfusion of oxygen, the ventilation to perfusion ratio (VA/Q), and the partial
pressure of oxygen in arterial blood (P3O2) are all indicators of emphysema severity [1].
1.4.2.3 Respiratory and Peripheral Muscle Dysfunction
Although COPD affects the lungs directly, significant systemic consequences
may occur, such as respiratory and peripheral muscle dysfunction [1-4]. The extent to
which respiratory muscles are affected in COPD patients siiil remains unclear, but some
aspects have been described. More specifically, the diaphragm of COPD patients seems
to be affected [31]. Due to the overload placed upon this respiratory muscle, the
diaphragm initially shows a greater resistance to fatigue [31]. During the early stages of
the disease, the inspiratory muscles of patients with COPD generate a greater force as
compared to healthy individuals [31]. However, patients with COPD also experience
hyperinflation, which places the respiratory muscles at a disadvantage (i.e. compromised
inspiratory muscle strength and endurance) [31]. Due to this muscular disadvantage, the
diaphragm begins to remodel itself to adapt to the physiological needs [31]. In a study
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conducted by Levine et al. [32], the remodelling of the diaphragm was found to decrease
its force due to adaptations occurring through fiber type transformation as well as
adaptations taking place within each muscle fiber type [32]. Evidence suggests that the
diaphragmatic fiber type switches from type Il (glycolytic) to type I (oxidative) which is a
fatigue-resistant fiber type as compared to type Il fibers [32]. There also seems to be a
competition for oxygen, in COPD patients during exercise, between the respiratory and
peripheral muscles in favour of the respiratory muscles. This is known as the "steal"
effect [1,31, 33].
Peripheral muscle dysfunction has been identified as another important systemic
consequence associated with this disease. The quadriceps, more specifically the vastus
lateralis muscle, has been the most studied muscle group linked to peripheral muscle
fatigue [34]. To date, muscle fatigue has been linked with specific peripheral muscle
alterations, such as a switch in muscle fiber type to more fatigable fibers (switch from
type I to type Il fibers) [34], muscle atrophy and weakness [35], reduced oxidative
capacity, and lactic acid build-up [36]. Peripheral muscle dysfunction has also shown to
be a predictor of mortality [37].
1.4.2.4 Exercise Intolerance
Exercise intolerance is a complex consequence of COPD [27]. It is closely
related to disability and impairment, and is a strong predictor of quality of life [27, 38].
Exercise intolerance can stem from a multitude of intricate mechanisms and interactions
frequently present among patients with COPD. These include a reduced ventilatory
capacity (reduced expiratory flow rates), a decreased exercise capacity (decrease in
peak work rate, maximal VO2 or endurance time to constant-load exercise), the
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presence of dynamic hyperinflation (decrease in inspiratory capacity), symptom
perception during exercise (dyspnoea and leg fatigue being reached at lower intensities),
hypoxemia (oxygen desaturation), and peripheral muscle fatigue [27]. The contribution
from each of these factors varies greatly from one individual to another [27].
During exercise, COPD patients will increase their minute ventilation, mostly via
an increase in breathing frequency, to compensate for the increased ventilatory demand
[30]. This increase in respiratory frequency will reduce the time between breaths, thus
making it increasingly difficult to fully empty the lungs [30]. This vicious cycle will result in
dynamic hyperinflation and could thus lead to premature exercise termination due to
breathlessness [30].
Leg fatigue is another symptom often reported by patients with COPD as a
limiting factor to exercise, prior to the occurrence of physiological limits of the body being
attained (VO2) [27]. A study conducted by Saey and colleagues [39] examined the
relationship between muscle fatigue and exercise response and found that even after
the administration of a bronchodilator, patients with greater susceptibility to leg fatigue
did not obtain a significant improvement in exercise capacity with bronchodilation. This
shows that peripheral muscle dysfunction may play a significant role in exercise
intolerance among COPD patients [39]. It is important to note that the type of exercise
modality chosen (e.g. walking versus cycling) seems to affect the degree and the source
of exercise intolerance in this patient population [27, 40]. A study conducted by Pepin
and coworkers [27], compared the response of COPD patients to a cycle endurance test
to their response to an endurance shuttle walk test [37]. The cycling test was found to
induce greater levels of perceived leg fatigue as compared to the walking test, whereas
the shuttle walk test induced greater levels of dyspnoea [37].
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1.4.2.5 Pulmonary Complications
Respiratory exacerbations are the most frequent pulmonary complication among
COPD patients. According to the American Thoracic Society and European Respiratory
Society [1, 2], an exacerbation of COPD is defined as "an event in the natural course of
the disease characterised by a change in the patient's baseline dyspnoea, cough and/or
sputum beyond day-to-day variability sufficient to warrant a change in management". On
average, COPD patients experience two exacerbations per year and approximately half
of all exacerbations are caused by acquiring an infection [3]. Management of an
exacerbation should include careful assessment along with an increased dosage of
inhaled short-acting beta2-agonist and/or an anticholinergic drug [3]. Antibiotics and/or
oral corticosteroids are also often prescribed during this time [3]. If severe enough,
patients might also be prescribed oxygen therapy [3]. To date, there is no classification
of exacerbations that has been established [1, 2]. However, several well known
indicators exist such as the requirement of hospital admittance; the presence of a high-
risk co-morbid condition, an obvious increase in dyspnoea, difficulty sleeping or eating,
worsening hypoxaemia and/or hypercapnia, changes in mental status, uncertain
diagnosis, inadequate home care, and the inability for the patient to care for them self [1,
2]-
Aside from exacerbations, COPD patients can be faced with other pulmonary
complications such as pulmonary hypertension [41]. Pulmonary hypertension evolves
due to the constriction of pulmonary arteries, making it much more difficult for the right
heart to pump blood through the lungs [42]. Eventually, this resistance in the lungs may
result in vascular remodelling, such as thickening of the blood vessels (intimai
hyperplasia) and smooth muscle hypertrophy [42]. In addition, as blood pressure rises
within the lungs, the heart's right ventricle has to pump to a greater extent thereby
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causing hypertrophy of the myocardium [42]. Due to the greater workload exerted on the
heart, right heart failure could occur [1]. Right heart failure occurs when the right heart in
unable to supply sufficient blood supply to the lungs in order for reoxygenation to occur;
this then affects oxygenated blood supply to the left heart and subsequently to the rest of
the body [42].
1.4.2.6 Anxiety and Depression
Like in many other chronic diseases, patients with COPD tend to present with
both anxiety and depression [1]. However, they are the least-treated comorbidities of
COPD [43]. In a systematic review [44] of 64 studies comparing rates of anxiety and
depression in various diseases, the prevalence of depression in COPD patients was
found to range from 37 to 71%, and that of anxiety from 50 to 75% which was
comparable to other chronic diseases such as renal disease, heart disease, AIDS, and
cancer. However high the prevalence rates are, less than one third of COPD patients
receive appropriate treatment [45, 46]. If left untreated, depression and anxiety can have
major implications such as increased number of consultations with their physician,
increased frequency of hospital admission, prolonged hospital stay, lower treatment
adherence, as well as poor quality of life and premature death [46]. Depression among
COPD patients has also been found to predict dyspnoea, fatigue, and disability [47, 48].
Symptoms of depression include hopelessness, pessimism, difficulties concentrating,
and social withdrawal [49]. Symptoms of anxiety include difficulties concentrating,
sweating, tachycardia, and dyspnoea [43]. Possible treatments consist of
pharmacotherapy and psychotherapy [43].
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1.5 Clinical Assessment of COPD
1.5.1 Diagnosis
Individuals with the previously mentioned comorbidities as well as a history of a
significant exposure to the potential risk factors should be considered for possible
diagnosis [2]. Diagnosis of COPD requires that a spirometry test be performed [1, 2].
Spirometry is a common pulmonary function test that measures expiratory flow rates and
three of the four lung volumes (all except RV) [1]. Patients must have a post-
bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity
(FVC) ratio < 0.7 to confirm the presence of airflow limitation that is not fully reversible
[2]. Through the results of a spirometry test, disease severity can be classified into four
stages (I through IV) (Table 1) [1]. It is recommended that a spirometry test be
performed after a bronchodilator is administered (e.g. 400 pg salbutamol) [2]. Patients
with airflow limitation in their 40's or 50's and especially those with a family history of
COPD should also be tested for a-1 -antitrypsin deficiency [1, 2].
Table 1.1 - Spirometry Classification of COPD
________Severity Based on Post-Bronchodilator FEV;
Stage Severity FEV1 % pred Post-
BronchodilatorFEV1ZFVC
I Mild >80 <0.70
II Moderate 50-80 <0.70
III Severe 30-50 <0.70
IV Very severe < 30 or <50 plus <0.70
chronic
________________________respiratory failure
FEV1: forced expiratory volume in one second; FVC: forced vital
capacity; respiratory failure: arterial partial pressure of Oxygen
(PaO2) less than 8.0 kPa (60 mmHg) with or without arterial
partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50
mmHg) while breathing air at sea level.
Adapted from GOLD [1]
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1.5.2 Investigations
Further investigations should include gathering a thorough medical history,
performing a physical examination, and exercise testing if required [1]. A detailed history
should be conducted for any patient suspected of having COPD and should include the
following: medical history, family history of COPD, identification of risk factors and
possibilities for reducing them, pattern of symptom development, history of previous
exacerbations and hospitalizations, presence of comorbidities, appropriateness of
current medical treatments, impact of disease on patient's life, and family/social support
[1].
A physical assessment is important to detect any signs of COPD prior to disease
progression. Physical signs are infrequently diagnostic in nature due to the fact that they
are typically not apparent until significant impairment of lung function has already
transpired [1]. During assessment, medical examiners should look for the following
signs: central cyanosis (bluish color), chest wall abnormalities (horizontal ribs, barrel
chest, protruding abdomen), flattening of the hemi-diaphragms, accelerated heart rate,
shallow breathing, pursed-lip breathing, resting respiratory muscle activation while
supine, and ankle/lower leg oedema [1]. In addition to an examination, a medical
evaluator should palpitate surrounding areas in addition to listening for any wheezing or
inspiratory crackles [1].
Cardiopulmonary exercise tests such as the six-minute shuttle walking test or an
exercise test performed on a cycle ergometer or treadmill are often conducted in patients
with COPD [1]. Indications for clinical exercise testing in this population include
evaluating exercise capacity for prognosis, impairment/disability assessment and/or
exercise prescription, identifying factors that contribute to exercise limitation, as well as
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1.6 Management of COPD
COPD is a preventable and
manageable disease [1, 3]. Although
this disease cannot be cured with
current available therapy, it is possible
to slow down a patient's descent
through the COPD downward spiral
(figure 2) with modern management of
the disease [5, 8]. Treatment should
include a management strategy combining pharmacotherapy and non-
pharmacotherapeutic interventions [3]. The goals of such interventions are to prevent
disease progression, reduce the frequency and severity of exacerbations, improve
health-status, improve health-related quality of life, and reduce mortality [3]. A
comprehensive approach, as illustrated in Figure 3, has been suggested for optimal
management of COPD [3].
Invalidity
Poor quality of life
Figure 1.2 COPD downward spiral. Adapted from Ia
Clinique du Souffle la Solane, Osséja, France.
1.6.1 Smoking Cessation
Tobacco is a highly addictive substance and tobacco smoking is considered a
chronic relapsing disorder [2]. Smoking cessation programs are the single most effective
and cost-effective strategy for preventing and treating those with COPD and should
therefore be considered as the primary intervention [1, 3]. Approximately 41% of
smokers try to quit smoking every year; however only 10% achieve and maintain this
goal [3]. Thus, it is imperative that all smoking COPD patients or those at risk of
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developing this disease be offered a smoking cessation intervention in order to increase
the chances of cessation [1, 3]. Effective interventions include counselling from
iSurgery'.
Oxygen







MRC dyspnea f ||—
scale ?
Early diagnosis Prevent/Rx AECOPD
{spirometry) + Follow-up
prevention
Figure 1.3 A comprehensive approach to the management of chronic obstructive
pulmonary disease (COPD). AECOPD = Acute exacerbation of COPD; LABA = long-
acting beta2-agonist; MRC = medical research council; PRN = as needed; Rx =
treatment.
Taken from CTS COPD Recommendations [23]
physicians and other health care professionals, self-help and community based
programs, as well as medications [1]. The use of medications such as nicotine
replacement therapy (gums, transdermal patches, and nasal sprays) and antidepressant
bupropion, approximately doubles smoking cessation rates [3]. Recent evidence has
Very severe
End of life care
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also suggested that exercise training can be used as an aid to smoking cessation [50,
51].
1.6.2 Self-Management
Self-management plays an important role in COPD. According to Bourbeau et al.
[52], self-management is a term used to describe "any patient education program aimed
at teaching skills needed to carry out medical regimens specific to the disease, guide
health behaviour change, and provide emotional support for patients to control their
disease and live functional lives". The same authors conducted a multi-centered
randomized controlled trial examining the impact of a self-management program on the
use of hospital services and health outcomes among moderate to severe COPD patients
[52]. The self-management program through disease specific education ("Living Well
with COPD"), weekly and monthly follow-up phone calls, and the availability of case
managers for advice and treatment supervision was shown to reduce hospital
admissions, emergency department and unscheduled physician visits, and to improve
I lealth-related quality of life [52]. These results show the importance of self-management
care among this patient population.
1 .6.3 Pharmacotherapy
Pharmacotherapy is central to reduce symptoms and/or complications [5]. This
form of treatment differs from one individual to another and is based on disease severity
and frequency of exacerbations [3]. Three main types of pharmacotherapy treatments
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are commonly prescribed for COPD patients: bronchodilators, anti-inflammatories, and
vaccines.
Bronchodilators are a class of medications which relax smooth muscle around
the airways thus improving expiratory flow rates and reducing hyperinflation [3]. Three
common types of bronchodilators include: ß-agonists, anticholinergic drugs, and
mythelxanthines [3]. Bronchodilators are normally administered through an inhaler or
nebulizer [3]. Short-acting bronchodilators, such as anticholinergics (e.g., ipratropium
bromide) and ß2-agonists (e.g., albuterol), have been shown to improve dyspnoea,
pulmonary function, and exercise tolerance in moderate to severe COPD patients [3].
Long-acting agents (e.g., salmeterol, tiotropium) are more effective than short-acting
bronchodilators [3]; indeed, greater benefits in chronic dyspnoea, pulmonary function,
and health-status have been observed with the long-acting agents in this patient
population [3]. Common side-effects of bronchodilators include tachycardia, heart
palpitations, irritability, insomnia, muscle cramps, and tremors [3]. Methylxanthines (e.g.,
theophylline) are another form of bronchodilator (weaker form) which is administered
orally [2, 3]. This medication offers modest improvements in dyspnoea, pulmonary
function, and exercise performance compared with other bronchodilators [3]. In general,
patients on this medication should be prescribed the lowest possible dose (8-14 pgdL"1)
due to inherent cardiovascular and neurological adverse effects [1, 3].
Anti-inflammatories, such as inhaled corticosteroids (ICSs), are also commonly
prescribed to patients with COPD. The use of ICSs unaccompanied by other
medications remains a controversial issue due to conflicting effects on a multitude of
outcomes such as symptoms, pulmonary function, airway inflammation, frequency and
seventy of exacerbations, and health status [3]. Randomized controlled trials have yet to
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show significant results pertaining to the improvement in lung function through the use of
this medication [3]. Side-effects include ecchymosis, dysphonia, oral candidiasis,
cataracts, glaucoma, pneumonia, and a decrease in bone density [3]. However,
combinations medications including bronchodilators and ICSs have proven to be
effective [1-3].
Vaccines are highly recommended for patients with COPD to prevent acute
exacerbations from occurring [3]. The two most common are influenza vaccines and
pneumococcal vaccines [3]. It is recommended that patients receive one influenza
vaccine per year whereas pneumococcal vaccines should be administered once every 5
to 10 years [3]. It has been shown that annual influenza shots reduce morbidity and
mortality by 50% in elderly patients, and reduces hospitalizations by 39% in patients with
chronic lung disease [3]. The specific benefits of pneumococcal vaccines are less
understood and are therefore recommended to be administered less frequently [3].
It is important to note that none of the current medications has been shown to
alter the decline in lung function that occurs over time in COPD patients [5]. In addition,
the effects of COPD medications on exercise tolerance, peripheral muscle function, and
quality of life are modest compared to those of certain non-pharmacological
interventions, such as pulmonary rehabilitation [53].
1.6.4 Oxygen Therapy
Oxygen therapy is a form of treatment carried out through the administration of
supplemental oxygen in hypoxemic patients. This form of treatment benefits the patient
by increasing the supply of oxygen to the lungs, thereby increasing the amount of
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oxygen available for the body tissues. The preferred methods to determine whether a
patient requires this form of treatment are an arterial blood gas assessment (PaO2) and
surveillance of arterial oxygen saturation via pulse oximetry (Sp02) [2]. Physiological
indications for oxygen therapy include having a resting arterial oxygen partial pressure
(PaO2) < 7.3 kPa (55 mmHg) as well as an SpO2 < 88% [2]. Concerning arterial oxygen
saturation, the goal through the use of this treatment is to maintain a SpO2 > 90% during
sleep, rest, and exertion [2]. It is possible for those who are physically active to require
oxygen therapy only during exercise or physical activities; in such cases, a portable
oxygen tank can be used [2]. It is equally possible for patients with COPD to be
prescribed oxygen therapy only during exacerbations [2]. In this case, prescription of
oxygen therapy needs to be re-evaluated 30-90 days afterward by rechecking arterial
blood gas [2]. Sources of oxygen include gas, liquid, and concentrator [2]. Educating
patients on this form of treatment is essential and has been shown to improve
compliance rates [2].
1.6.5 Surgery
Few surgical treatments are available for COPD patients. One such treatment is
lung volume reduction surgery [ ij. This type of surgery involves the removal of parts of
the lung. By removing the diseased lung tissue, the remaining healthier tissue can have
an enhanced performance [1]. Lung volume reduction surgery has been shown to
reduce hyperinflation, reduce the frequency of exacerbations, improve expiratory flow
rates, increase maximal work capacity, and improve health-related quality of life [1]. This
type of surgery is an expensive procedure and is only recommended for a select few [1].
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In patients with very severe COPD, lung transplantation surgery has been shown
to improve functional capacity and quality of life [1]. To be referred for such an
intervention, patients must have the following criteria: FEVi < 35% predicted, PaO2 < 7.3
- 8.0 kPa (55-60 mm Hg), PaCO2 > 6.7 kPa (50 mm Hg), and secondary pulmonary
hypertension [1]. Limitations for this type of surgery include shortage of donor lungs,
possible complications (including death during surgery, acute rejection of donor lung,
bronchiolitis obliterans), infection, and its cost (ranges from $1 10,000 to over $200,000
US) [1]. Individual risk factors are assessed through examination of patient history,
physical examination, chest x-ray, and pulmonary function tests [1]. Surgery might be
contraindicated for some patients, for example being at high risk of death due to poor
lung function or experiencing an exacerbation pre-surgery [1].
1.6.6 Pulmonary Rehabilitation
Pulmonary Rehabilitation (PR), which combines exercise training, patient
education and psychosocial support, has become widely recognized as a cornerstone in
the management of COPD because it is the best available intervention to tackle the
systemic consequences of the disease [5, 7, 8r 53, 54].
In a recent statement from the American Thoracic Society and European
Thoracic Society [31], PR was defined as "... an evidence-based, multidisciplinary, and
comprehensive intervention for patients with chronic respiratory diseases who are
symptomatic and often have decreased daily life activities." The goals of PR are to
reduce symptoms, optimize functional status, improve health-related quality of life
(HRQL), and reduce health care costs [55, 56]. In a meta-analysis of 23 randomized
controlled trials in COPD, PR was shown to significantly reduce dyspnoea, increase
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exercise tolerance, and improve HRQL compared with standard care [57]. Emerging
evidence is also beginning to document its effectiveness in reducing respiratory
exacerbations [58] and hospital days [59-63].
Exercise training is considered the key to successful PR because it is
responsible for much of the benefits associated with this intervention [31, 59]. Exercise
training has been shown to improve exercise tolerance (peak oxygen consumption
(V02peak)- peak work rate, or endurance time to constant-load exercise) in COPD
patients despite the absence of improvement in resting lung function [59]. Improvements
in exercise tolerance are mediated by several physiological mechanisms, including a
reduction in minute ventilation for any given work rate [59], a desensitization to the
sensation of dyspnoea [59], and an improvement in skeletal muscle strength [59] and
oxidative capacity [59]. In the daily life of COPD patients, these physiological
adaptations translate into less dyspnoea for any given task [59], a greater ability to
perform various activities [59], and a better health-related quality of life [64]. After initial
scepticism in the early 1980s [65], the therapeutic role of exercise training in COPD has
now gained widespread acceptance, as evidenced by its inclusion in Canadian [31],
American/ European [2], and World Health Organization [1] guidelines for the
management of COPD.
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1.7 Exercise Training in Pulmonary Rehabilitation: How Much Is Enough?
There is considerable variability worldwide in the way PR programs deliver their
exercise component [53, 54]. This is largely attributable to the fact that the optimal
exercise dose (intensity, duration, and frequency of training sessions) for PR has not
been determined. As a result, the current guidelines for exercise training in PR are rather
ambiguous. In their 2006 statement on PR [54], the American Thoracic Society and
European Thoracic Society made the following recommendations with regards to the
exercise dose: "A minimum of 20 sessions should be given at least three times per week
to achieve physiologic benefits; twice-weekly supervised plus one unsupervised home
session may also be acceptable. High-intensity exercise produces greater physiologic
benefits and should be encouraged; however, low-intensity training is also effective for
those patients who cannot achieve this level of intensity. [...] The total effective training
time should ideally exceed 30 minutes. However, for some patients, it may be difficult to
achieve this target training time or intensity, even with close supervision."
In reality, no systematic studies have been conducted to establish the optimal
duration or frequency of training sessions in PR. Current guidelines regarding session
duration are based on evidence obtained in healthy individuals [66], while
recommendations for frequency of training sessions stem from clinical trials of PR
versus usual care that were not designed to determine optimal training dose [67, 68].
Furthermore, the evidence favouring high-intensity over moderate- or low-intensity
training in COPD patients is limited. The contention that "high-intensity training produces
greater physiologic benefits and should be encouraged" [54] comes from one small
(n = 19) randomized clinical trial from Casaburi and colleagues [69], in which the
physiological training effects of a high training work rate (~ 80% of peak work rate) were
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compared to those of a low training work rate (^ 50% of peak work rate). At program
completion (week 8), the high training work rate was found to elicit greater physiological
adaptations (reductions in lactate levels and minute ventilation for a given work rate) and
larger gains in exercise tolerance and was therefore deemed optimal [69].
A major issue with the use of exercise training at 80% of peak work rate in PR is
that compliance to this training intensity has been shown to be problematic for COPD
patients [53, 70]. In a group of 42 patients enrolled in a 12-week program, this target
intensity was achieved by 0, 3, 5, and 5 patients at weeks 2, 4, 10, and 12, respectively
[70]. In light of this compliance issue, other approaches to exercise training, such as
training at the ventilatory threshold, have been proposed as more tolerable, less
unpleasant, and thus possibly easier to comply with for COPD patients. The ventilatory
threshold is commonly described as the breakpoint in the ventilatory response to
incremental exercise above which minute ventilation increases disproportionately in
response to increments in oxygen consumption [71]. This breakpoint does not occur at
the same percentage of peak capacity for all individuals, and thus needs to be
determined on an individual basis with incremental exercise testing. Training at the
ventilatory threshold is associated with tolerable levels of ventilation and dyspnoea, a
particularly valuable feature for a patient population limited by those two factors during
exercise [26, 28, 72]. The effectiveness of exercise training at the ventilatory threshold
was compared to that of training at a standardized moderate intensity (50% of heart rate
reserve) in 24 patients with moderate COPD [71]. Despite the fact that the mean training
intensity was similar between both groups, training at the ventilatory threshold led to
larger physiological adaptations (greater reductions in lactate levels, CO2 excretion, and
minute ventilation for a given workload) than training at the standardized moderate
intensity [71]. This approach to training was also shown to be effective at improving
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muscular strength and endurance in a subsequent study conducted by the same group
[73].
The chronic effects of training at the ventilatory threshold (i.e. effects of several
weeks or months of training) in COPD patients are therefore promising [25, 27, 71].
However, the contention that it is more tolerable, less unpleasant and easier to comply
with than high-intensity exercise training has yet to be investigated. The affective
response to this form of exercise has, to our knowledge, never been examined in COPD
patients.
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1.8 Affective Valence: Definition, Measurement, and Relationship with
Exercise
1.8.1 Definition
According to Ekkekakis et al., the term "affect" is defined as "the most basic
component of all valenced responses (i.e. positive or negative, pleasant or unpleasant),
including, but not limited to, emotions and moods." [74] Affect is broader than an
emotion, the main difference being that an emotion requires cognitive appraisal, which
can generate positive or negative implications on one's ambitions or well-being [74].
According to Lazarus et al. [75], "emotions are generated and controlled by the personal
implications for well-being conveyed by relationships with the environment and
comprehended through an appraisal process which draws heavily on evolved
intelligence and knowledge." In other words, individuals decide what to feel after
interpreting or explaining what has happened. Moods, on the other hand, are also
thought to have a cognitive origin. In comparison with emotions, moods are not
responses to specific events; they are responses to how we view the world [76]. Simply
stated, affect is a broader feeling than an emotion or mood. Essentially, it is the
difference between a pleasant versus an unpleasant feeling.
Within exercise psychology, there has been much deliberation on how to best
define affective response in relation to exercise [77]. Thus far, researchers have made
use of categorical as well as dimensional approaches. Watson, Clark and Tellegen [78]
declared that affect is composed of two primary dimensions termed positive affect (PA)
and negative affect (NA). This would be classified as a categorical approach which
organizes affective responses into distinct categories [79]. On the other hand, the
dimensional approach is "based on the assumption that affective states are interrelated
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and can be understood by a parsimonious set of underlying dimensions" [79]. These
dimensions include positive and negative affect as well as high and low arousal. Positive
affect (PA) includes feelings such as active, enthusiastic, and alert [78]. The negative
affect (NA) dimension reflects feelings such as anger, disgust, guilt, and fear [78].
Furthermore, several dimensions exist within PA and NA. High/low PA or high/low NA
describes the level of arousal felt by the participant.
1.8.2 Measurement of Affective Response
The measurement of affect is a highly controversial issue [80]. The dilemma on
whether to use a categorical measurement versus a dimensional measurement is at the
heart of this controversy [80]. Current views advocate that both approaches possess
advantages and limitations, which will depend on the specific research question needing
to be answered [76]. Researchers interested in examining specific emotions (positive
and negative affect) should choose a categorical approach whereas researchers wanting
to examine basic affect (positive and negative affect as well as high and low arousal)
should select a dimensional approach [81]. To date, various measurement tools have
been used to measure affective response. Table 2 presents an overview of some of
these tools.
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Table 1.2 - Overview of Some Self-Reported Measures of Affect
Reference Measure Construct No. Of
Items
McNair et al. [82] POMS
Gauvin & Rejeski [83] EFI
Watson, Clark & Tellegen PANAS
[84]
Spielberger, Gorsuch & STAI
Lushene [85]
Zuckerman & Lubin [86] MAACL
Mood
Exercise- induced feeling
Positive and Negative Affect
Anxiety




Mackay et al. [89]
AD-ACL Various transitory arousal states
PACES Exercise enjoyment
SACL Stress and Arousal
McAuley & Courneya [90] SEES Exercise-induced feeling states
Lox et al. [91] PAAS Feeling state
Monk [92] VAS(GVA Global vigor and affect
specific)
POMS = Profile of Mood States, EFI = Exercise-Induced Feeling Inventory, PANAS = Positive and
Negative Affect Schedule, STAI = State-Trait Anxiety Inventory, FS = Feeling Scale, MAACL = Multiple
Affect Adjective Checklist, AD-ACL = Activation Deactivation Adjective Checklist, PACES = Physical
Activity Enjoyment Scale, SACL = Stress/Arousal Adjective Checklist, SEES = Subjective Exercise
Experiences Scale, PASS = positive affect/sensation-seeking measure, VAS = Visual Analogue Scale,













1.8.3 Affective Response and its Relationship to Acute Exercise
Reviewing the literature on the exercise-affect relationship is a difficult and a
challenging task [93]. Variations in methodology, mainly in the measurement of affect,
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definition of intensity, and the choice of exercise dose, make it difficult to formulate any
direct comparisons among studies [80].
To date, a common belief has been that acute exercise is usually associated with
unpleasant feelings, which might explain why few individuals exercise or adhere to an
exercise program [80]. As well, in the realm of the exercise-affect relationship, a
common belief has been that exercise performed at moderate-intensities, versus low or
high intensities, leads to acute positive affective responses and should therefore be
prescribed to all individuals involved in an exercise program [80]. Based on these
traditional assumptions, researchers have attempted to provide clarification on the
mechanisms involved in the relationship between exercise intensity and adherence
through the study of affective response [74]. Currently, this area of research is
expanding and studies have shown that exercise intensity is negatively related to acute
pleasure responses [80] and long-term adherence [94, 95] to an exercise program .
A large extent of research has focused on the dose-response relationship
between acute exercise and affect [80, 96]. The reason for this interest has been based
on the notion that a specific exercise intensity and duration will elicit a certain affective
response. Thus far, the common beliefs for exercise have been that moderate intensity
elicits positive affective changes [97-99], low intensity is suspect to bring about any
changes in affect (76-80), and high intensity is likely to be unpleasant [97-100].
However, researchers have argued that this relationship in an acute condition is possibly
dependent on inter-individual differences and therefore cannot be generalized to the
entire population [101]. Possible inter-individual differences suggested include; the
individual's personal goals and objectives from exercising, initial aerobic fitness, the
physical and social environment, how the individual perceives the exercise stimulus, as
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well as the psychological state of the individual [80]. As well, exercise duration of single
bouts have not been shown to have an impact on affective changes [102, 103].
Furthermore, it has been shown that affect during acute exercise is negatively correlated
with physiological responses of metabolic strain, such as heart rate, respiratory rate,
oxygen consumption, and blood lactate levels [104, 105].
1.8.4 Affective Response to Acute Exercise Among COPD Patients
To date, few studies have looked at affective response to acute exercise training
among COPD patients. A study performed by Carrieri-Kohlman et al. [106], examined
whether patients with COPD at rest and during acute exercise could make the
distinction between affective response to dyspnoea and perceived shortness of breath
[106]. This study defined affective response as distress and anxiety experienced from
dyspnoea [106]. They used several visual analogue scales to measure breathing effort,
shortness of breath, as well as distress and anxiety associated with dyspnoea [106].
Results indicated that COPD patients exercising in acute conditions can, in fact,
differentiate the sensation of dyspnoea from affective response [106].
Another study performed by Carrieri-Kohlman et al. [107] looked at dyspnoea
and affective response during long-term exercise training in subjects with COPD. This
randomized clinical trial included 45 dyspnoea-limited patients with COPD who
underwent a 12-week exercise training program with and without nurse coaching [107].
The 12 week program was divided into 4 weeks of supervised treadmill training and 8
weeks of home walking [107]. This study defined affective response as simply
dyspnoea-related anxiety and used a visual analogue scale and the state-trait anxiety
inventory as measurement tools [107]. The objectives of the study were to compare
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dyspnoea intensity, dyspnoea-related anxiety, and exercise performance [107]. Results
showed that dyspnoea-related anxiety rapidly decreased within the first 4 sessions
despite constant levels of dyspnoea intensity [107]. Further investigation revealed that
exercise training with coaching is as effective when compared to exercise training alone
in improving exercise performance, dyspnoea, anxiety, and distress [107].
Finally, a study performed by Gayle et al. [108], examined psychological change
among 15 COPD patients undergoing an exercise program. The treatment group
underwent psychological and physiological assessments followed by 28 weeks of
exercise training [108]. The control group, in contrast, did not participate in the initial 14
weeks of exercise training [108]. This study did not define affect directly, but measured
anxiety and depression using the state-trait anxiety inventory (STAI) and the Self-Rating
Depression Scale [108]. Contrary to other studies, results indicated that exercise did not
have any significant impact on anxiety or depression [108].
In summary, the evidence regarding the relationship between affect and exercise
in COPD patients is scarce and inconsistent. Furthermore, prior investigations have
used surrogate rather than direct measures of affect, such that the affective response to
an acute bout of exercise in COPD patients remains unknown.
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1.9 Acute Physiological Response to Exercise Training Among COPD
Patients
Thus far, few researchers have attempted to investigate the acute physiological
response to an exercise-training bout among COPD patients. Most researchers have
investigated long-term physiological adaptations to exercise programs [60, 71].
Sabapathy et al. [109] have specifically examined the acute physiological response to
single exercise bouts of continuous high-intensity training (70% of peak VO2) and
interval training. Results showed that high-intensity training was found to induce higher
levels of ventilation, lung hyperinflation and dyspnoea than interval training which
resulted in patients performing a reduced total amount of work [110].
A study conducted by Maltais et al. [70] examined the physiological response in
moderate to severe COPD patients undergoing a pulmonary rehabilitation program.
Forty-eight COPD patients were asked to perform 25-30 minute exercise sessions on a
calibrated ergocycle [70]. These exercise sessions were held 3 times per week for a total
of 12 weeks with a target intensity of 80% Wmax [70]. Results showed that although
most participants were unable to tolerate high-intensity exercise, physiological changes
did occur with the exception of resting pulmonary function [70]. Participants were shown
to have significant (p<0.0002) increases in V02max and Wmax, reductions in lactic acid




Rational and Clinical Significance
Current PR guidelines advocate high-intensity exercise training (at « 80% of peak
work rate) for patients with COPD. However, this training intensity has been shown to be
unachievable in a large proportion of patients. Alternative approaches to exercise
training, including training at the ventilatory threshold, have thus been proposed as more
tolerable, less unpleasant, and thus possibly easier to comply with in this patient
population. However, this belief has yet to be investigated by comparing the acute
affective and physiological response to different exercise-training protocols in COPD
patients. To date, few studies have examined the relationship between exercise and
affect in patients with COPD undergoing exercise training. In addition, to our knowledge,
no study has simultaneously assessed both affective and physiological responses to an
exercise-training bout in COPD patients.
The general aim of the present study was to identify which protocol, between
high-intensity training and training at the ventilatory threshold, is more pleasurable and
tolerable for COPD patients. The proposed research project will improve our
understanding of the affective response to different exercise training protocols among
COPD patients undergoing a PR program. Clinically, the significance of this study is to
determine which protocol patients find more pleasant/unpleasant, with the rationale that





Research Objectives and Hypotheses
The purpose of the present study was to compare, in COPD patients, the acute
affective and physiological response to a single bout of exercise-training performed
using the following protocols: i) high intensity training at 80% of peak work rate (CT80)
and ii) training at the ventilatory threshold (CTVT). More specifically, our primary
research objective was to compare the acute affective response (i.e. pleasant versus
unpleasant feelings), as measured by the PANAS, to a single bout of exercise-training
for CT80 and CTVT to determine if the latter approach is in fact perceived as less
unpleasant for COPD patients. The secondary objectives were to: i) compare the acute
affective response, as measured by the GVA, between CT80 and CTVT, and ii) to
compare the acute physiological response to both training protocols.
Our research hypotheses were that: 1) training at the ventilatory threshold would
be associated with greater positive affective response compared to the high-intensity
exercise-training group (as measured by the PANAS and GVA instrument); and 2) high-
intensity exercise would induce higher levels of VO2, VE, HR, dynamic hyperinflation




Acute Affective and Physiological Response to Exercise Training in Chronic Obstructive
Pulmonary Disease: A Pilot Study
Primary Author
Amanda K. Rizk, B. Sc, amanda_rizk@hotmail.com
Co-Authors
Simon L. Bacon, simon.bacon@concordia.ca
Emilie Chan-Thim, e.chanthim@gmail.com
Kim L. Lavoie, kiml_lavoie@yahoo.ca
Myriam De Lorimier, myriam.delorimier@crhsc.rtss.qc.ca
Véronique Pepin, v-pepin@crhsc.rtss.qc.ca
Institution
Axe de recherche en santé respiratoire, Hôpital du Sacré-Cœur de Montréal
Amanda Rizk, B.Sc. (kinesiology) Montreal Behavioural Medicine Centre, Hôpital du
Sacré-Cœur de Montréal, master's student, Department of Exercise Science, Concordia
University.
Simon L. Bacon, Ph.D. (Behavioral Medicine), Montreal Behavioural Medicine Centre,
Hôpital du Sacré-Cœur de Montréal Assistant Professor, Department of Exercise
Science, Concordia University.
Emilie Chan-Thim, B.Sc. (kinesiology) Hôpital du Sacré-Cœur de Montréal, master's
student, Department of Exercise Science, Concordia University.
Kim L Lavoie, Ph.D. (psychology) Montreal Behavioural Medicine Centre, Hôpital du
Sacré-Cœur de Montréal, Associate Professor, Department of psychology, UQAM.
Myriam De Lorimier, P.T. Hôpital du Sacré-Cœur de Montréal.
Véronique Pepin, Ph.D. (kinesiology), Montreal Behavioural Medicine Centre, Hôpital




Purpose: Pulmonary rehabilitation (PR) guidelines advocate high-intensity exercise
training for patients with chronic obstructive pulmonary disease (COPD) yet this
approach is unachievable for a large proportion of patients. Alternative approaches, such
as training at the ventilatory threshold, have been proposed as more tolerable, less
unpleasant, and thus possibly easier to comply with for the COPD clientele. This
assumption remains to be verified. The study aim was to compare, in COPD patients,
the acute affective and physiological response to high-intensity training (CT80) versus
training at the ventilatory threshold (CTVT). Methods: Subjects were randomly assigned
to perform a bout of either CT80 or CTVT on a cycle ergometer. Affective response to
the exercise bout was measured using the Positive and Negative Affect Schedule
(PANAS) and the Global Vigor and Affect Instrument (GVA). Physiological response to
the same bout was measured breath by breath using portable equipment. Results:
Thirteen subjects (CT80 = 7; CTVT = 6) completed all assessments. Positive affect
scores from the PANAS increased from pre-, to end-, to post-exercise (time
effect)(F=17.56, p=0.0005), but this increase was significant for the CTVT group only
(time by intervention interaction)(F=5.85, p=0.02). No significant time or interaction effect
was observed for global affect or global vigor from the GVA. Irr addition, no significant
difference in physiological response was observed between CT80 and CTVT.
Conclusion: The main finding from this pilot study is that affect seems to improve after
an exercise-training bout in COPD patients, especially when the protocol used is training
at the ventilatory threshold.
Keywords: COPD, affective response, physiological response, exercise training
45
Introduction
Pulmonary rehabilitation (PR), which combines exercise training, patient
education and psychosocial support, has become widely recognized as a cornerstone in
the management of COPD because it is the best available intervention to tackle the
systemic consequences of the disease [5, 7, 8, 53, 54]. Exercise training is considered
the key to successful PR because it is responsible for much of the benefits associated
with this intervention [8, 53, 54]. Exercise training has been shown to improve exercise
tolerance in COPD patients despite the absence of improvement in resting lung function
[111]. Improvements in exercise tolerance are mediated by several physiological
mechanisms, including a reduction in minute ventilation for any given work rate [69], a
desensitization to the sensation of dyspnoea [112], and an improvement in skeletal
muscle strength [112] and oxidative capacity [69, 113]. In the daily life of COPD patients,
these physiological adaptations translate into less dyspnoea for any given task [114], a
greater ability to perform various activities [115], and a better health-related quality of life
[1 1 1]. After initial scepticism in the early 1980s [65], the therapeutic role of exercise
training in COPD has now gained widespread acceptance, as evidenced by its inclusion
in Canadian [8], American/ European [7], and World Health Organization [5] guidelines
for the management of COPD.
There is considerable variability worldwide in the way PR programs deliver their
exercise component [53, 54]. Current PR guidelines advocate high-intensity exercise
training [7, 8]. Yet, the evidence favouring high-intensity over moderate- or low-intensity
training in COPD patients is limited [17]. A major issue with the use of high-intensity
exercise training in PR is that compliance to this training intensity has been shown to be
problematic for COPD patients [53, 70]. In light of this compliance issue, other
approaches to exercise training have been proposed as more tolerable, less unpleasant,
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and thus possibly easier to comply with for COPD patients. Exercise training at the
ventilatory threshold has been suggested as one of these alternatives to high-intensity
training [24, 25]. The ventilatory threshold is commonly described as the breakpoint in
the ventilatory response to incremental exercise above which minute ventilation
increases disproportionately in response to increments in oxygen consumption [71]. In
clinical trials, the chronic effects of training at the ventilatory threshold in COPD patients
have been promising [24, 26]. However, the belief that this form of training is more
tolerable, less unpleasant, and easier to comply with for COPD patients than high-
intensity training has yet to be verified.
Very few studies have compared the acute physiological response to different
exercise-training protocols in COPD patients. Training at the ventilatory threshold has
been shown to be associated with tolerable levels of ventilation and dyspnoea, a
particularly valuable feature for a patient population limited by those two factors during
exercise [26, 28, 72]. However, its acute physiological effects have yet to be directly
compared to those of high-intensity exercise training.
Even fewer studies have examined the acute affective response to exercise
training in COPD patients. The term "affect" can be defined as "the most basic
component of all valenced responses (i.e. positive or negative, pleasant or unpleasant),
including, but not limited to, emotions and moods" [74]. Simply stated, it is the
differentiation between a pleasant and an unpleasant feeling. To date, a common belief
has been that acute exercise is associated with unpleasant feelings, which would explain
why few individuals undertake or adhere to an exercise program [80]. As well, in the
realm of the exercise-affect relationship, a common belief has been that exercise
performed at moderate intensities, versus low or high intensities, leads to acute positive
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affective responses and should therefore be prescribed to all individuals involved in an
exercise program [80]. In healthy individuals, studies have shown that exercise intensity
is negatively related to acute pleasure responses [80] and to long-term adherence to an
exercise program [94, 95]. However, the acute affective response to different exercise-
training protocols in COPD patients has yet to be examined.
The primary research objective of the present study was to compare, in
individuals with COPD, the acute affective response to a single bout of exercise training
performed using the following protocols: i) high intensity training at 80% of peak work
rate (CT80) and ii) training at the ventilatory threshold (CTVT). The secondary objective
was to compare the acute physiological response to both training protocols. The ultimate
aim of the study was to verify whether CTVT is, in fact, more pleasant (affectively) and
more tolerable (physiologically) than CT80 for individuals with COPD.
Methods
Subjects
Thirteen subjects were recruited from a pool of individuals who previously agreed
to participate in the larger pulmonary rehabilitation trial at the Hôpital du Sacré-Coeur de
Montréal. Eligibility was ascertained according to the following criteria: Inclusion criteria:
1) clinically stable COPD; 2) age 40 years or older; 3) smoking history of at least 10
American pack-years (20 cigarettes per pack); 4) post-bronchodilation forced expiratory
volume in one second (FEV1) less than 80% of the predicted normal value; and 5) FEV1
to forced vital capacity (FVC) ratio less than 0.7. Exclusion criteria: 1) exacerbation of
respiratory symptoms in the past 4 weeks (change in dyspnoea or volume/colour of
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sputum, need for antibiotic treatment, or need for hospitalization); 2) any contraindication
to exercise testing based on guidelines from the American Thoracic Society [116]; 3) any
active condition other than COPD that can influence exercise tolerance (asthma,
unstable coronary heart disease, left congestive heart failure, neoplasia, severe
claudication, severe arthritis, etc.); 4) oxygen therapy; 5) participation in a PR program in
the past year; 6) inability to complete baseline evaluations (including the achievement of
a ventilatory threshold on the incremental cycling exercise test). These eligibility criteria
were mostly meant to differentiate COPD from other respiratory diseases and to ensure
clinical stability and patient safety. Figure 4.1 illustrates the flow of participants through
each stage of the study.
Study Design and Procedure
The present pilot study was a sub-study to a larger randomized, parallel-group
clinical trial (RCT) comparing the chronic effects of different exercise training protocols
on various pulmonary rehabilitation program outcomes. As part of the larger RCT,
patients who met the eligibility criteria and accepted to participate completed a thorough
baseline evaluation and were then randomly assigned in blocks of six to one of three
training protocols. Each subject trained three times per week for 12 weeks, for a total of
36 exercise sessions. Session duration was adjusted such that the total amount of work
performed per session was identical across the different protocols.
As a sub-study to the larger RCT, the present study followed the same design,
that is a randomized, parallel-group design. The specific objective of the present sub-
study was to compare the acute affective and physiological response to a single bout of
exercise training performed according to one of two different protocols which were part
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of the larger RCT: CT80 and CTVT. Both exercise protocols were performed on a cycle
ergometer where patients were asked to perform quiet breathing for 3 minutes, followed
by 5 minutes of unloaded pedalling (warm-up), followed by 25 minutes or more at the
target intensity, followed by 5 minutes of cool-down. Subjects who agreed to participate
in this sub-study accepted to be monitored closely and to complete additional
evaluations in the initial phase of their rehabilitation program. Further details regarding
baseline measurements from the RCT and additional measurements taken for this sub-
study are provided below.
Assessments
Baseline assessments
As mentioned earlier, baseline measurements were taken as part of the larger
RCT. These measurements included pulmonary function tests, exercise tests, a quality
of life questionnaire, a series of psychological questionnaires and a battery of cognitive
function tests. Of the above mentioned measures, pulmonary function tests and one
exercise test were used for the present study.
Pulmonary Function Testing
Spirometry, lung volumes, and lung diffusion capacity for carbon monoxide
(DLCO) were obtained at the time of enrolment according to recommended techniques
[117]. Values were compared to predicted normal values from the European Community
for Coal and Steel/European Respiratory Society [118].
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Exercise Testing
A symptom-limited incremental cycling exercise test was performed at baseline
to rule out the presence of cardiovascular co-morbidities and to determine the work rate
at peak effort and at the ventilatory threshold for subsequent exercise prescription.
Subjects were seated on an electromagnetically braked cycle ergometer (Ergometrics
800, SensorMedics, Yorba Linda, CA) and connected to an electrocardiogram and to a
respiratory circuit through a mouthpiece. The respiratory circuit consisted of a
pneumotachograph, O2 and CO2 analyzers, and a mixing chamber (Vmax Encore,
SensorMedics, Yorba Linda, CA). After five minutes of rest and three minutes of
unloaded pedalling, the workload was increased in a stepwise manner up to the
individual's maximal capacity. Each step lasted one minute and increments of 5 or 10
watts were used. This protocol is frequently used in respirology [119]. Gas exchange
parameters (minute ventilation, O2 uptake, CO2 excretion) and heart rate were measured
at rest and during exercise on a breath-by-breath basis. Dyspnoea and leg fatigue was
evaluated at rest and every other minute during the test with the modified 10-point Borg
scale [120]. The ventilatory threshold was determined using the V-slope method [121], a
computerized approach to identify the breakpoint in the VCO2-VO? relationship Peak
work rate was defined as the highest work rate maintained at a pedalling speed of at
least 50 revolutions per minute for a minimum of 30 seconds.
Measurements taken during training
To answer our specific research question, affective response, a series of
physiological parameters, and symptoms (dyspnoea and leg fatigue) were measured
during a single exercise training session in the initial phase of the rehabilitation program.
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More specifically, these measures were collected either before the beginning of the
training program or during one of the three weekly exercise sessions within the first two
weeks of program initiation. This timeframe was chosen i) to capture the acute response
to the training protocols before adaptations occur, and ii) to allow for a reasonable
window to obtain these measurements in as many subjects as possible from the larger
RCT. These measurements are described in detail below and the timeline of the
experimental design is depicted in Figure 4.2.
Affective Response
The acute affective response to exercise training was assessed using two
different scales: the Positive and Negative Affect Schedule (PANAS) and the Global
Vigor and Affect (GVA) instrument.
Positive and Negative Affect Schedule (PANAS): Subjects completed the PANAS at rest,
at completion of the exercise bout, and half an hour after the completion of the exercise
session. The PANAS, developed by Watson, Clark, and Tellegen [84], is a brief and
easy to administer questionnaire which provides measures on positive and negative
affect. More specifically, this questionnaire consists of 20 questions related to affect, 10
of which deal with positive affect responses (interested, excited, strong, enthusiastic,
proud, alert, inspired, determined, attentive, and active) and the remaining 10 dealing
with negative affect responses (distressed, upset, guilty, scared, hostile, irritable,
ashamed, nervous, jittery, and afraid) [122]. Its structure is consistent with the two-
dimensional circumflex model and has been shown to have excellent reliability [123] and
validity [122]. In addition, it has been shown to be highly internally consistent and largely
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uncorrelated [122]. Various time-frames have been used for the PANAS, yet the chosen
time-frame for the current study was "in the moment". This scale is a 5 point scale where
1 represents "very slightly or not at all", 2 represents "a little", 3 represents "moderately",
4 represents "quite a bit", and 5 represents "extremely". Individuals are asked to circle
one of the points on the scale to indicate to what extent they feel a given sentiment or
emotion in the moment. The final outcome is obtained in two separate scores: one for
positive affect and the other for negative affect. These scores can be calculated by
simply adding the chosen numbers for each. Scores can range from 10 to 50 for each
affective response.
Global Vigor and Affect (GVA) Instrument: At rest (pre-exercise), at the beginning of the
exercise bout (0%), halfway through the exercise bout (50%), at completion (100%), and
half an hour after the completion of the PR session (post-exercise), participants were
asked to rate their global affect and vigor using the GVA instrument which is composed
of several visual analogue scales. Visual analogue scales have an extended history in
the measurement of mood [124, 125] and have been shown to be highly reliable and
valid in assessing both global vigor and global affect [126, 127]. This scale is a simple
and frequently used measure which has been included in several studies to assess a
wide range of subjective phenomena such as dyspnoea, pain, fatigue, sleep loss, among
many others [126]. Each visual analogue scale is a 100 millimetre line separating
opposite extremes of the mood or state of arousal [126]. Subjects are asked to place a
mark on these continuums to demonstrate their overall affective state and state of
arousal for that particular moment [126]. The mark placed on this continuum, ranging
from 0 to 100, is then measured using a ruler. Four of the visual analogue scales are
related to global affect and the remaining four are related to global vigor. Each score is
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then entered into a separate equation revealing a global affect and vigor score ranging
from 0 to 100. The equations are the following:
GV = [(alert) + 300 - (sleepy) - (effort) - (weary)] / 4
and
GA = [(happy) + (calm) + 200 - (sad) - (tense)] / 4
Physiological Response
Physiological measurements were obtained with a wireless portable metabolic
system (Oxycon Mobile, Jaeger, Viasys Healthcare GmbH, Germany). The system
consists of a lightweight, battery-operated portable system mounted on the subjects'
body via a vest. It records breath-by-breath data through a facemask and subsequently
sends it to a host computer system through wireless transmission. Oxygen uptake (VO2),
carbon dioxide excretion (CO2), minute ventilation (VE), heart rate (HR), breathing
frequency (BF), and oxygen saturation (SpO2) were measured on a breath-by-breath
basis through the use of this portable system throughout the training session. In addition,
inspiratory capacities (IC) were measured at 5 minute intervals.
Symptoms and Compliance
Dyspnoea and leg fatigue, the main two symptoms which limit exercise in COPD
patients [128], were measured at rest, at the beginning of the training session, every 5
minutes during training, at the completion of training, and half an hour after the
completion of the PR session. Symptoms were measured using the modified 10-point
Borg scale [120]. Compliance to the training protocol was defined as the percent time
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spent at the prescribed training intensity during the single exercise-training bout. As
such, measured HR was compared to target HR for every minute of the exercise bout. If
measured heart rate was within ± 5 beats of target HR, the subject was considered
compliant for that minute. The final compliance rate was obtained by calculating the
following:
Time spent at target HR (min) X 100
Total time of intensity phase (min)
Statistical Analyses
To assess the effects of the different exercise protocols on PANAS and GVA,
four repeated-measures general linear models were conducted. These models used the
exercise protocol (CT80 or CTVT) as the between-factor independent variable
and assessment points as the within-factor repeated measure independent variable (3
levels for the PANAS and 5 levels for the GVA). For the assessment of the physiological
changes that occurred during the testing sessions, a series of repeated measures mixed
models were conducted. This analysis strategy was utilized due to the magnitude of
measures for each variable, thus increasing the likelihood of violating the regression
assumption of independence. In these analyses the exercise protocol was the only
between factor effect assessed. All analyses were conducted using SAS (v9.2, SAS
Institute, Cary NC).
For the purpose of this study, affective response was defined as any change in self-





A total of thirteen subjects completed the present study, seven of which were in
the CT80 group and six of which were in the CTVT group. The baseline characteristics
of the study group are presented in Table 4.1, and are typical of COPD samples in terms
of age and BMI. Participants had, on average, stage Il to stage III COPD according to
the GOLD classification, which is indicative of moderate to severe airflow obstruction [1J.
Subjects had a wide range of peak exercise capacities, as indicated by the wide range of
peak work rates and peak VO2.
Acute Affective Response to Exercise
Results from the PANAS questionnaire revealed a significant time effect
(F=17.56, p=0.0005) as well as a time by intervention interaction (F=5.85, p=0.02) for
positive affect scores. As shown in Figure 4.3, positive affect increased from rest to end-
exercise to post-exercise in both groups combined (time effect), but this increase was
significant for the CTVT group only (time ? intervention interaction). In contrast, no
significant changes in negative affect scores were obtained (Figure 4.3). Likewise,
results from the GVA questionnaire revealed no significant time or interaction effect for
global vigor (level of alertness) or global affect. Although not statistically significant, the
changes in GVA scores observed were in the same direction as those obtained with the
PANAS (Figure 4.4), meaning it had a tendency to increase from rest to post-exercise.
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Acute Physiological Response to Exercise
The mean physiological responses at the target intensity during the single
exercise training-bout for CT80 and CTVT are found in Table 4.2. In addition, the time
course for VO2 ,Ve , heart rate, and inspiratory capacity is depicted in Figure 4.5. As
illustrated, VO2 , Ve , and heart rate were higher in the CT80 group than in the CTVT
group at most exercise time points, possibly suggesting a greater physiological demand
from the CT80 protocol. Likewise, inspiratory capacity was lower for CT80 than CTVT at
all time points, indicating greater lung hyperinflation (air trapping) in the CT80 group.
However, despite these subtle differences, the interaction between the exercise protocol
and time was not significant for any of the four parameters. Our results thus suggest that
the CT80 and the CTVT protocols are similarly physiologically tolerable.
Acute Symptomatic Response and Compliance to Exercise
The symptomatic response to CT80 and CTVT is illustrated in Figure 4.6. As
clearly shown in this figure and confirmed by statistical analyses, the perceived ievels of
dyspnoea and leg fatigue were comparable between the two groups. Mean compliance
rates to the single bout of exercise were 88% for the CT80 group and 82% for the CTVT
group. These values were not significantly different.
Discussion
The present study compared, in COPD patients, the acute affective and
physiological response to different exercise training protocols (high-intensity training
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versus training at the ventilatory threshold) during a single exercise training bout. Our
findings suggest that affect improves after a single bout of exercise in this patient
population, especially if the protocol used is training at the ventilatory threshold. As well,
the acute physiological response to both CT80 and CTVT protocols do not appear to
differ significantly.
Reviewing the literature on the exercise-affect relationship is a difficult and a
challenging task [93]. Variations in methodology, mainly in the measurement of affect,
definition of intensity, and the choice of exercise dose, make it difficult to formulate any
direct comparisons among studies [80]. Previous investigations, in healthy individuals,
state that a common belief has been that acute exercise is associated with unpleasant
feelings, which could explain why few individuals take part or adhere to an exercise
program [80]. This belief is somewhat inconsistent with our findings which demonstrate
that a change in affect is possible after a single bout of exercise. However, results from
the GVA did indicate a dip in both global affect and global vigor halfway through the
exercise bout, but this dip was not statistically significant, possibly because of our small
sample size. This belief stemming from previous literature will therefore have to be
confirmed with a larger trial.
The current study also found an increase in positive affect from pre-exercise to
post-exercise using the PANAS. This change was especially true with the CTVT
protocol, which exposed subjects to an intensity that can be considered moderate. This
finding is consistent with the previous literature suggesting that exercise performed at
moderate intensities, versus low or high intensities, leads to acute positive affective
responses [80]. As well, in studies conducted in healthy individuals, exercise intensity
has been shown to be negatively related to acute pleasure responses [80]. The fact that,
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¡? the present study, positive affect increased in CTVT (moderate intensity), but not in
CT80 (high intensity) is in line with these previous investigations. However, the fact that
we found statistically significant findings with the PANAS but not with the GVA warrants
further investigation. The sensitivity of the GVA questionnaire during exercise will need
to be verified.
No studies, to our knowledge, have investigated the acute physiological
response to training at the ventilatory threshold. However, the acute physiological
response to continuous high-intensity training has been documented [109]. Sabapathy
and coworkers have reported on the acute physiological response to single exercise
bouts of continuous high-intensity training at 70% of peak VO2 in 10 individuals with
moderate COPD [109]. These investigators reported a significant degree of dynamic
lung hyperinflation (i.e. a significant drop in inspiratory capacity) with this form of
exercise [109]. The present study findings are not consistent with this observation from
Sabapathy et al. since inspiratory capacity did not decrease significantly with CT80. A
potential reason for our finding may be that subjects from the CT80 group were not truly
working at an intensity corresponding to 80% of their peak work rate, thereby not eliciting
the expected physiological response. This would have occurred if the exercise test
performed at baseline was not a true peak test. This aspect was not verified, but if an
underestimation of peak work rate occurred at baseline, it would have affected the CT80
group only, since the CT80 intensity is relative to peak work rate while CTVT intensity is
independent of it. Caution is warranted, however, at this point, with respect to the
conclusions to draw from this finding given our small sample size.
Dyspnoea upon physical exertion can be a major deterrent for COPD patients to
engage in physical activity, thereby reducing compliance [129]. The present study found
59
no differences ¡? symptomatic responses (i.e. dyspnoea and leg fatigue) between the
two exercise-training protocols. The finding regarding dyspnoea coincides with our
results for inspiratory capacity, where no statistically differences were found between the
CT80 and CTVT group. Inspiratory capacity is a physiological marker of dynamic
hyperinflation (i.e. air trapping), which is highly correlated with dyspnoea [130]. It is
therefore not surprising that no differences in dyspnoea was observed since no
statistically significant differences were found for inspiratory capacity between both
groups. As stated previously, if the exercise test performed at baseline was not a true
peak test and subjects were therefore not working at an intensity corresponding to 80%
of their peak work rate, this may be another potential reason why no differences were
found in subjective measurements of dyspnoea and leg fatigue between groups.
Finally, no differences in the compliance rates to the single bout of exercise were
obtained between the two groups. Subsequent compliance to the rest of the PR program
would give us more information about the effect of acute affective response to the
training protocol on long-term compliance. This aspect will have to be examined in a
future study.
In summary, the present study indicates that affect improves after a single
exercise-training bout in COPD patients. This seems especially true when the protocol
used is CTVT. The acute physiological response to both protocols did not differ
significantly. These preliminary results suggest that CTVT increases positive affect to a
greater degree than CT80, but is similarly tolerable than CT80 for the COPD clientele.
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Legends for Figures
Figure 4.1 Flow of Participants Through Each Stage of the Study
Figure 4.2 Timeline of the experimental design.
Figure 4.3 Positive and negative affect, as measured by the PANAS, for the CT80
(closed circles) and CTVT (open circles) groups. Values are mean ± SD.
Figure 4.4 Global affect and global vigor, as measured by the GVA, for the CT80
(closed circles) and CTVT (open circles) groups. Values are mean ± SD.
Figure 4.5 Time course and end-exercise values for VO2 (A), Ve (B), heart rate (C),
and inspiratory capacity (D) for the CT80 (closed circles) and CTVT (open circles).
Values are mean ± SD. Data is missing for inspiratory capacity in one individual.
Figure 4.6 Dyspnoea and leg fatigue perception using the modified 10-point Borg scale
for the CT80 (closed circles) and CTVT (open circles) groups. Values are mean ± SD.
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TABLES
Table 4.1 Characteristics of the Study Group
CT80 CTVT
Male/Female, ? 2/5 2/4
Age, years 64.6 ± 7.9 72.3± 8.9
BMI, kgrrï2 28.3 ±4.1 25.8 ±5.7
FEV11L 1.57 ±0.32 1.40 ±0.23
FEV1, % predicted 66.7 ± 15.5 64.2 ± 17.2
FEWFVC, % 40.4 ± 19.7 50.5 ±12.1
Peak Work Rate, W 65.7 ± 20.5 70.8 ± 27.6
V02peak, L-miiT1 ' 1.09±0.21 1-.00 ±0.31
Values presented are Mean ± SD.
BMI, Body Mass Index; FEV1, Forced Expiratory Volume in 1 second; FVC, Force Vital
Capacity; V02peak, peak O2 Uptake.
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Table 4.2 Mean Physiological Response to the Target Intensity for CT80
and CTVT
CT80 CTVT
Time at Target Intensity, min 25 ± 0 29.67 ± 2.58
VO2, L/min 0.74 ±0.14 0.69 ±0.192
VE, L/min 30.67 ± 5.84 26.43 ± 8. 1 8
HR, b/min 115.26 ±16.89 92.77 ±17.94
? IC, L -0.065 ± 0.071 -0.005 ± 0.284
Dyspnoea, Borg 3.4 ±1.49 3.7 ± 2.36
Leg Fatigue, Borg 3.3 ± 1 .59 3.3 ± 1 .65
Values presented are mean ± SD.
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This scale consists of a number of words that describe the different feelings and
emotions. Read each item and then circle the appropriate answer next to that word.
Indicate to what extent you feel these sentiments or emotions in this moment. Use the



























Global Vigor and Affect (GVA) Instrument
Name Day Date / / Time
How alert do you feel?
Very little
How sad do you feel?
Very little
How tense do you feel?
Very little
How much of an effort is it to do anything?
Very little
How happy do you feel?
Very little
How weary do you feel?
Very little
How calm do you feel?
Very little
How sleepy do you feel?
Very little
very much
very much
very much
very much
very much
very much
very much
very much
